Cover Image
市場調查報告書

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364838
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析 Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 56 Pages
簡介

本報告提供以葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的概要

治療藥的開發

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各開發階段

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各治療範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各適應症

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :企業開發中的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的治療藥開發企業

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • Hua Medicine (Shanghai) Ltd.
  • LG Life Science LTD.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Poxel SA
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • vTv Therapeutics Inc
  • Yuhan Corporation

藥物簡介

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :暫停中的計劃

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中止的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0103TDB

Summary

Global Markets Direct's, 'Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016', provides in depth analysis on Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2)
  • The report reviews Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Overview
  • Therapeutics Development
    • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Stage of Development
    • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Therapy Area
    • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Indication
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Companies
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Companies Involved in Therapeutics Development
    • Advinus Therapeutics Ltd
    • Amgen Inc.
    • Hua Medicine (Shanghai) Ltd.
    • LG Life Science LTD.
    • Ligand Pharmaceuticals, Inc.
    • Novartis AG
    • Poxel SA
    • Takeda Pharmaceutical Company Limited
    • Teijin Pharma Limited
    • vTv Therapeutics Inc
    • Yuhan Corporation
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Drug Profiles
    • AM-9514 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKM-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-280391 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCZ-960 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sinogliatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMG-123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTP-399 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-GKA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Dormant Projects
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Discontinued Products
  • Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Featured News & Press Releases
    • Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity
    • Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
    • Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial
    • Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
    • Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug
    • Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control
    • Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics
    • Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients
    • Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial
    • Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013
    • Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial
    • Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes
    • Sep 07, 2010: GKM-001 Completes Phase I Single Ascending Dose Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Advinus Therapeutics Ltd, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Hua Medicine (Shanghai) Ltd., H1 2016
  • Pipeline by LG Life Science LTD., H1 2016
  • Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Poxel SA, H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Pipeline by Teijin Pharma Limited, H1 2016
  • Pipeline by vTv Therapeutics Inc, H1 2016
  • Pipeline by Yuhan Corporation, H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top